Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MESO

Mesoblast Ltd ADR

Dec 11 • 04:00PM ET

10.43

Dollar change -0.77
Percentage change -6.87	%

Healthcare • Biotechnology • Australia • NASD

Peers: BMRN SRPT IONS SGMO BLUE ALNY FATE CARA CYTK KPTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	-	Shs Outstand	85.82M	Perf Week	-8.91%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-0.39	Insider Trans	-	Shs Float	-	Perf Month	7.14%
Income	-87.71M	PEG	-	EPS next Q	-	Inst Own	1.36%	Short Float	-	Perf Quarter	63.74%
Sales	5.89M	P/S	202.08	EPS this Y	36.03%	Inst Trans	-	Short Ratio	7.04	Perf Half Y	45.26%
Book/sh	4.21	P/B	2.48	EPS next Y	31.58%	ROA	-	Short Interest	1.42M	Perf Year	421.55%
Cash/sh	0.55	P/C	18.91	EPS next 5Y	48.80%	ROE	-	52W Range	1.61 - 12.19	Perf YTD	374.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.34%	ROI	-15.05%	52W High	-14.44%	Beta	3.54
Dividend TTM	-	Quick Ratio	1.18	Sales past 5Y	2.11%	Gross Margin	-166.13%	52W Low	547.83%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	1.18	EPS Y/Y TTM	16.39%	Oper. Margin	-996.33%	RSI (14)	48.66	Volatility	4.24% 5.41%
Employees	73	Debt/Eq	0.25	Sales Y/Y TTM	-	Profit Margin	-1488.95%	Recom	1.00	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	10.96%	Payout	-	Rel Volume	1.06	Prev Close	11.20
Sales Surprise	-38.79%	EPS Surprise	-47.51%	Sales Q/Q	-3.91%	Earnings	Aug 28 AMC	Avg Volume	201.97K	Price	10.43
SMA20	-5.26%	SMA50	4.47%	SMA200	46.09%	Trades		Volume	214,578	Change	-6.87%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-24	Upgrade	Maxim Group	Hold → Buy	$12
Aug-29-24	Upgrade	Jefferies	Hold → Buy
Jul-23-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $11
Aug-31-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Downgrade	Maxim Group	Buy → Hold
Aug-04-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-04-23	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $2
Mar-09-23	Initiated	William Blair	Outperform	$8
Dec-06-22	Downgrade	Jefferies	Buy → Hold
Sep-06-22	Initiated	Piper Sandler	Overweight	$7
Apr-07-21	Upgrade	Maxim Group	Hold → Buy	$18
Dec-22-20	Downgrade	Maxim Group	Buy → Hold
Dec-04-20	Downgrade	Chardan Capital Markets	Neutral → Sell	$7.50
Oct-22-20	Initiated	RBC Capital Mkts	Sector Perform	$12
Aug-14-20	Reiterated	Maxim Group	Buy	$16 → $22
May-28-20	Reiterated	H.C. Wainwright	Buy	$14 → $21
Jan-31-19	Resumed	H.C. Wainwright	Buy	$6.50
Mar-22-18	Downgrade	Credit Suisse	Neutral → Underperform
Feb-28-18	Reiterated	Cantor Fitzgerald	Buy	$20 → $23
Aug-31-17	Initiated	Oppenheimer	Outperform	$16

Show Previous Ratings

Dec-05-24 06:29AM	Mesoblasts Revascor Therapy Shows Promise in Heart Failure (TipRanks)
Dec-04-24 06:32PM	FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease (GlobeNewswire)
Dec-02-24 06:20PM	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation (GlobeNewswire)
Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
06:30AM	Loading…
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)
Aug-27-24 07:25PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Jul-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 (GlobeNewswire)
Jul-23-24 07:53AM	FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire) +9.54%
Jul-21-24 08:45PM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain (GlobeNewswire)
Jul-08-24 08:37PM	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire)
Jul-02-24 08:04AM	Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates (Zacks)
07:37AM	Loading…
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
01:55AM	Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week (GlobeNewswire)
Jun-02-24 08:23PM	Mesoblast Corporate Presentation at Investor Conference (GlobeNewswire)
Apr-29-24 09:05PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 (GlobeNewswire) +13.78% -7.04%
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-27-24 11:00AM	Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (Zacks) -11.20%
Mar-25-24 10:34PM	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire) +78.64%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-13-24 07:30PM	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer (GlobeNewswire) -8.27%
Mar-10-24 07:54PM	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) (GlobeNewswire)
Mar-03-24 08:25AM	Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-28-24 05:57PM	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 (GlobeNewswire) -5.74%
Feb-26-24 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-14-24 07:46PM	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire) +5.96%
Jan-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 (GlobeNewswire)
11:30AM	Loading…
Jan-19-24 11:30AM	Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug (Zacks) +11.63%
Jan-18-24 06:36PM	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire)
Nov-27-23 07:28AM	Mesoblast files applications with US FDA for HLHS therapy (Pharmaceutical Business Review)
Nov-26-23 06:56PM	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease (GlobeNewswire)
Nov-21-23 06:32PM	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD (GlobeNewswire) +10.74%
Oct-30-23 08:04PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023 (GlobeNewswire) +5.98%
Sep-26-23 06:18AM	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee (GlobeNewswire)
Sep-22-23 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Sep-21-23 03:30AM	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval (GlobeNewswire)
Aug-30-23 07:07PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023 (GlobeNewswire) +12.59%
Aug-29-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly) -58.90%
Aug-03-23 08:10PM	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children (GlobeNewswire)
Jul-30-23 08:31PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023 (GlobeNewswire)
Jun-04-23 08:21PM	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role (GlobeNewswire)
May-25-23 07:28PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023 (GlobeNewswire) +5.22%
May-24-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Apr-27-23 09:00PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-25-23 08:47PM	Mesoblast Completes Private Placement (GlobeNewswire)
Mar-21-23 09:20PM	FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing (GlobeNewswire)
Mar-07-23 07:03PM	FDA Accepts Mesoblasts Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023 (GlobeNewswire) -5.90% +23.76%
Feb-27-23 05:13PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022 (GlobeNewswire)
04:49PM	DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC) (GlobeNewswire)
Feb-26-23 07:38PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-16-23 06:16PM	Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy (GlobeNewswire) -7.82%
Feb-08-23 06:09PM	FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain (GlobeNewswire)
Jan-31-23 06:30PM	Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) (GlobeNewswire) +8.79%
04:40AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Dec-22-22 07:18PM	Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility (GlobeNewswire)
Dec-15-22 12:00PM	Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know (Zacks) -5.15%
Dec-02-22 03:13PM	Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit (Simply Wall St.)
Nov-23-22 09:38AM	Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease (Benzinga)
Nov-22-22 06:32PM	Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire)
06:01PM	Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 (GlobeNewswire)
Nov-21-22 06:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire) +5.50%
Oct-30-22 07:50PM	Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022 (GlobeNewswire)
Oct-02-22 07:52PM	Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD (GlobeNewswire)
Aug-30-22 07:05PM	Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022 (GlobeNewswire) +8.42%
Aug-29-22 08:14PM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Aug-18-22 07:00AM	Jane Bell Joins Mesoblast Board (GlobeNewswire)
Jul-29-22 07:05AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Jul-11-22 08:40PM	Rexlemestrocel-L to be Highlighted at Maxims Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management (GlobeNewswire) -5.12%
Jun-28-22 11:54PM	The past five years for Mesoblast (ASX:MSB) investors has not been profitable (Simply Wall St.)
Jun-23-22 12:05PM	INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL (GlobeNewswire)
Jun-20-22 12:06PM	AVAILABILITY OF THE 2021-2022 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE COMPOSITION OF THE BOARD OF DIRECTORS, APPOINTMENTS AND REAPPOINTMENTS OF DIRECTORS PROPOSED AT THE SHAREHOLDERS' GENERAL MEETING OF JULY 26, 2022 (GlobeNewswire)
Jun-09-22 07:00AM	Mesoblast Key Opinion Leader Event Series for Investors & Analysts (GlobeNewswire)
May-31-22 08:15PM	Operational Highlights and Financial Results for the Period Ended March 31, 2022 (GlobeNewswire)
May-08-22 08:15PM	Perenti Global (ASX:PRN) shareholders have endured a 44% loss from investing in the stock three years ago (Simply Wall St.)
May-05-22 08:40PM	What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry? (Simply Wall St.)
Apr-28-22 08:35PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-13-22 10:25AM	BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study (Zacks)
Mar-28-22 09:30PM	Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript (Motley Fool)
Mar-23-22 08:40PM	Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board (GlobeNewswire) -6.92% +6.47%
Feb-27-22 05:18PM	Is Mesoblast (ASX:MSB) Using Debt In A Risky Way? (Simply Wall St.)
Feb-24-22 05:30PM	Operational Highlights and Financial Results for the Period Ended December 31, 2021 (GlobeNewswire)
05:57AM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Feb-20-22 06:19PM	Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohns Colitis After Direct Injection of Remestemcel-L by Colonoscopy (GlobeNewswire)
Feb-01-22 07:20PM	Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer (GlobeNewswire)
Jan-30-22 07:16PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Jan-24-22 06:45PM	Mesoblast to Participate in Edison Groups Global Healthcare Open House Virtual Conference From January 25-27th, 2022 (GlobeNewswire)
Jan-11-22 08:26PM	Single Dose of Mesoblasts Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease (GlobeNewswire)
Dec-30-21 06:38PM	Mesoblast Provides Update Following Meeting With FDAs OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease (GlobeNewswire)
Dec-15-21 07:09PM	FDAs OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program (GlobeNewswire) +19.18%
10:00AM	Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO) (Zacks)
Dec-13-21 07:18PM	Update on Novartis Agreement (GlobeNewswire) -6.49% -27.60%
Dec-05-21 06:47PM	Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia (GlobeNewswire)
Dec-02-21 04:57PM	Shareholders in Mesoblast (ASX:MSB) are in the red if they invested a year ago (Simply Wall St.) -5.20%
Dec-01-21 10:00AM	Mesoblast Limited (MESO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-29-21 10:00AM	Wall Street Analysts Believe Mesoblast Limited (MESO) Could Rally 157%: Here's is How to Trade (Zacks)
Nov-23-21 06:09PM	Operational Highlights and Financial Results for the Period Ended September 30, 2021 (GlobeNewswire)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your FINVIZ experience